Nuvig Therapeutics raised $161 million in a Series B funding round co-led by Sanofi Ventures and Blue Owl Healthcare Opportunities to support the clinical development of its novel immunomodulatory therapeutics.
Nuvig Therapeutics raised $161 million in a Series B funding round co-led by Sanofi Ventures and Blue Owl Healthcare Opportunities to support the clinical development of its novel immunomodulatory therapeutics.
12/05/24, 12:34 PM
Location
menlo parkMoney raised
$161 million
Industry
therapeutics
biotechnology
health care
Round Type
series b
Investors
Mission Bio Capital, Digitalis Ventures, Bristol Myers Squibb, Platanus, Novo Holdings A/S, Abrdn Inc., Alexandria Venture Investments, Lotte Holdings, Global Bio Access Fund, Leaps By Bayer, B Capital, Norwest Venture Partners, Blue Owl Healthcare Opportunities, Sanofi Ventures
Nuvig Therapeutics announced the closing of a $161 million Series B financing to advance its novel immunomodulatory therapeutics for patients with inflammatory autoimmune diseases. The financing will support clinical proof-of-concept studies for lead candidate NVG-2089 and the company's preclinical pipeline.
Company Info
Location
menlo park, california, united states
Additional Info
Nuvig Therapeutics is advancing innovative and transformational therapies that are designed to induce natural mechanisms to restore immune homeostasis, rebalance immune function following inflammation, and improve the treatment options for patients. Nuvig is building a pipeline of novel immune therapeutics for chronic inflammatory and autoimmune diseases.